Cigna Infliximab Users Get $500 To Switch To Biosimilars
Remicade Users Receive $500 Debit Card To Move Onto Preferred Drugs From Amgen And Pfizer
Program aims to share rebate savings from preferred drugs, ease treatment disruptions. Products like Remicade covered under medical benefits require new kinds of incentives for switching.
You may also be interested in...
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.